TY - JOUR
T1 - Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation
AU - Vela-Ojeda, J.
AU - García-Ruiz Esparza, M. A.
AU - Reyes-Maldonado, E.
AU - Jiménez-Zamudio, L.
AU - García-Latorre, E.
AU - Moreno-Lafont, M.
AU - Estrada-García, I.
AU - Montiel-Cervantes, L.
AU - Tripp-Villanueva, F.
AU - Ayala-Sánchez, M.
AU - García-León, L. D.
AU - Borbolla-Escoboza, J. R.
AU - Mayani, H.
N1 - Funding Information:
Acknowledgements This work was partially supported by grant no. 2004-123 from FOFOI (Fondo de Fomento a la Investigación, Dirección de Prestaciones Médicas, Coordinación de Investigación en Salud, Instituto Mexicano del Seguro Social, México).
PY - 2006/2
Y1 - 2006/2
N2 - To analyze the relationship between the cellular composition of peripheral blood allografts and clinical outcome, we performed a prospective study in 45 adult patients who underwent allogeneic peripheral blood hematopoietic stem cell transplantation (HSCT) from a histocompatibility leukocyte antigen identical sibling donor for different hematological malignancies. The dose of CD34+, CD3+, CD4+, CD8+, and CD19+ lymphocytes, natural killer (NK) cells, natural killer T (NKT) cells, type 1 and type 2 dendritic cells (DC1 and DC2), as well as regulatory T (Treg) lymphocytes was analyzed. All patients were conditioned with busulphan and cyclophosphamide (BuCy2) ± VP-16 and received a short course of methotrexate and cyclosporin-A as graft-versus-host disease (GVHD) prophylaxis. Acute GVHD (aGVHD) was present in 9 of 43 (21%) patients, and chronic GVHD (cGVHD) developed in 18 of 39 (46%) patients. There was a significantly higher incidence of aGVHD in patients receiving more than 6×106/kg CD34+ cells. In univariate analysis, variables associated with better survival were as follows: a dose of less than 1.5×107/kg NKT cells and less than 1.7×106/kg DC2 for disease-free survival (DFS), and a dose of less than 3×107/kg NK cells, less than 1.5×107/kg NKT cells, less than 3×106/kg DC1, and less than 1.7×106/kg DC2 for overall survival (OS). In the Cox regression analysis, the dose of NKT cells was the only variable associated with better DFS, while the doses of NK, NKT, and CD34+ cells (less than 8×106/kg) were associated with better OS. In conclusion, different circulating cell populations, other than CD34+ cells, are also of relevance in predicting the clinical outcome after allogeneic peripheral blood HSCT.
AB - To analyze the relationship between the cellular composition of peripheral blood allografts and clinical outcome, we performed a prospective study in 45 adult patients who underwent allogeneic peripheral blood hematopoietic stem cell transplantation (HSCT) from a histocompatibility leukocyte antigen identical sibling donor for different hematological malignancies. The dose of CD34+, CD3+, CD4+, CD8+, and CD19+ lymphocytes, natural killer (NK) cells, natural killer T (NKT) cells, type 1 and type 2 dendritic cells (DC1 and DC2), as well as regulatory T (Treg) lymphocytes was analyzed. All patients were conditioned with busulphan and cyclophosphamide (BuCy2) ± VP-16 and received a short course of methotrexate and cyclosporin-A as graft-versus-host disease (GVHD) prophylaxis. Acute GVHD (aGVHD) was present in 9 of 43 (21%) patients, and chronic GVHD (cGVHD) developed in 18 of 39 (46%) patients. There was a significantly higher incidence of aGVHD in patients receiving more than 6×106/kg CD34+ cells. In univariate analysis, variables associated with better survival were as follows: a dose of less than 1.5×107/kg NKT cells and less than 1.7×106/kg DC2 for disease-free survival (DFS), and a dose of less than 3×107/kg NK cells, less than 1.5×107/kg NKT cells, less than 3×106/kg DC1, and less than 1.7×106/kg DC2 for overall survival (OS). In the Cox regression analysis, the dose of NKT cells was the only variable associated with better DFS, while the doses of NK, NKT, and CD34+ cells (less than 8×106/kg) were associated with better OS. In conclusion, different circulating cell populations, other than CD34+ cells, are also of relevance in predicting the clinical outcome after allogeneic peripheral blood HSCT.
KW - Clinical outcome
KW - Dendritic cells
KW - NK
KW - NKT
KW - Regulatory T cells
KW - Stem cell transplantation
UR - http://www.scopus.com/inward/record.url?scp=30744453033&partnerID=8YFLogxK
U2 - 10.1007/s00277-005-0037-5
DO - 10.1007/s00277-005-0037-5
M3 - Artículo
SN - 0939-5555
VL - 85
SP - 113
EP - 120
JO - Annals of Hematology
JF - Annals of Hematology
IS - 2
ER -